Gerresheimer AG/€GXI

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Gerresheimer AG

Gerresheimer AG is a prominent player in the healthcare and life sciences industry, specializing in the production of glass and plastic products for pharmaceutical and cosmetic packaging. The company’s key offerings include pharmaceutical vials, prefillable syringes, glass and plastic packaging for drugs, as well as delivery systems for the safe administration of medications. Founded in 1864, Gerresheimer has evolved into a global entity with headquarters in Düsseldorf, Germany, and operates manufacturing sites in Europe, the Americas, and Asia. Its strategic strength lies in a broad product portfolio and advanced technical expertise, enabling it to cater to the stringent requirements of its diverse clientele in the healthcare sector. The company’s comprehensive geographic footprint and commitment to innovation bolster its competitive position in the market.

Ticker

€GXI
Sector

Primary listing

XETRA

Employees

13,616

Gerresheimer AG Metrics

BasicAdvanced
€1.5B
23.85
€1.83
0.78
€0.04
0.09%

Bulls say / Bears say

Shares surged nearly 4% on August 5 after Gerresheimer announced plans to sell its moulded glass business, showing investor confidence in improved growth and margins from its focus on pharma and biotech packaging (Reuters).
Gerresheimer reaffirmed its medium-term organic revenue growth target of 6–9% and an adjusted EBITDA margin of 23–25%, underscoring management’s confidence in sustainable profitability improvements (Reuters).
CEO Dietmar Siemssen reiterated strong long-term prospects for containment solutions and drug delivery systems for biologics, especially GLP-1 injection pens for weight-loss drugs like Wegovy, leveraging a fast-growing market (Reuters).
Gerresheimer cut its 2025 revenue outlook for the second time to just 0–2% organic growth, underlining ongoing weak demand in the cosmetics and oral liquids segments (Reuters).
Active Ownership, which now holds a 5.31% stake in Gerresheimer, has called for a faster strategic review and cost cuts after shares dropped 36% year-to-date, signaling shareholder dissatisfaction with management execution (Reuters).
The company cut its dividend for the 2024 financial year to €0.04 per share from €1.25 to safeguard financial flexibility, potentially reducing shareholder returns and highlighting cash-flow pressures (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €GXI

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs